Stay updated on Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial page
- CheckyesterdayChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check8 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check16 days agoChange DetectedThe page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an updated version number from v2.16.0 to v2.16.1.SummaryDifference1.0%
- Check23 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check30 days agoChange DetectedThe page has removed a citation regarding a study on plasma biomarkers in renal cell carcinoma, which included an erratum reference.SummaryDifference0.3%
- Check45 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
Stay in the know with updates to Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial page.